A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
AstraZeneca
Astellas Pharma Inc
Parabilis Medicines, Inc.
Coherus Oncology, Inc.
I-Mab Biopharma US Limited
ALX Oncology Inc.
Imugene Limited
IGM Biosciences, Inc.
Immodulon Therapeutics Ltd
Tyme, Inc
Taiho Pharmaceutical Co., Ltd.
EMD Serono
AstraZeneca
Daiichi Sankyo
Eli Lilly and Company
mAbxience Research S.L.
Amgen
Galectin Therapeutics Inc.
Sanofi
Sanofi
Sanofi
Sanofi
Bayer
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
AstraZeneca
Sanofi
AstraZeneca
Sanofi
Pfizer
Mast Therapeutics, Inc.